S&P 500
7,226.20
+0.01%
Dow Jones
49,494.60
-0.62%
Nasdaq 100
27,685.40
+0.66%
Russell 2000
2,804.78
-0.02%
FTSE 100
10,364.50
0.00%
Nikkei 225
59,260.50
-0.78%

Investing

Sepracor’s (SEPR) Shares Now Cut In Half

Photo of Douglas A. McIntyre
By Douglas A. McIntyre Published
Follow 24/7 Wall St. on Google
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Being in the pharmaceutical development business has always been rough, and investors in Sepracor (SEPR) learned that lesson again today. The company’s shares are down after earnings, off 17% to $31.85. The stock has a 52-week high of $63.24.

For the three months ended June 30, 2007, total revenues increased to approximately $278.1 million, which reflected a 5.2% increase from second quarter 2006 revenues of $264.4 million. Net income for the quarter was approximately $6.1 million, or $0.05 per diluted share compared to $11.0 million, or $0.10 per diluted share for the second quarter of 2006.

Both sales and earnings missed Wall St. hopes.

According to Reuters: Revenue from Lunesta, the company’s popular insomnia drug, grew just slightly, to $143.0 million from $139.1 million a year ago as generic competition weighed.

Generics will hurt a company like SEPR more than its Big Pharma rivals because it has fewer drugs on the market and less in the pipeline. If one product starts to get hit by competition, revenue can be hit hard, and for a long time.

The prospects here look none too good, but neither does the stock price

Douglas A. McIntyre

Photo of Douglas A. McIntyre
About the Author Douglas A. McIntyre →

Douglas A. McIntyre is the co-founder, chief executive officer and editor in chief of 24/7 Wall St. and 24/7 Tempo. He has held these jobs since 2006.

McIntyre has written thousands of articles for 24/7 Wall St. He is an expert on corporate finance, the automotive industry, media companies and international finance. He has edited articles on national demographics, sports, personal income and travel.

His work has been quoted or mentioned in The New York Times, The Wall Street Journal, Los Angeles Times, The Washington Post, NBC News, Time, The New Yorker, HuffPost USA Today, Business Insider, Yahoo, AOL, MarketWatch, The Atlantic, Bloomberg, New York Post, Chicago Tribune, Forbes, The Guardian and many other major publications. McIntyre has been a guest on CNBC, the BBC and television and radio stations across the country.

A magna cum laude graduate of Harvard College, McIntyre also was president of The Harvard Advocate. Founded in 1866, the Advocate is the oldest college publication in the United States.

TheStreet.com, Comps.com and Edgar Online are some of the public companies for which McIntyre served on the board of directors. He was a Vicinity Corporation board member when the company was sold to Microsoft in 2002. He served on the audit committees of some of these companies.

McIntyre has been the CEO of FutureSource, a provider of trading terminals and news to commodities and futures traders. He was president of Switchboard, the online phone directory company. He served as chairman and CEO of On2 Technologies, the video compression company that provided video compression software for Adobe’s Flash. Google bought On2 in 2009.

Continue Reading

Douglas A. McIntyre |

CTSH: Cognizant Growth Slowing A Bit More Than Expected

By William Trent, CFA of Stock Market Beat
Douglas A. McIntyre |

ADBE: Adobe Systems Earnings

By William Trent, CFA of Stock Market Beat Over the weekend we made our forecast for the Adobe Systems (ADBE)…
Douglas A. McIntyre |

NetFlix (NFLX) Comes Back, A Little

NetFlix (NFLX) lost 12% of it market value today and fell as low as $17.17. That was until Wall St.…
Paul Ausick |

Pfizer Overcomes Currency Exchange Issue with Stronger Sales of Cancer Drugs

ThinkstockPfizer Inc. (NYSE: PFE) reported second quarter 2015 results before markets opened Tuesday morning. The company reported quarterly adjusted diluted…
Douglas A. McIntyre |

Lowe’s Beats, Up In Pre-Market

Lowe’s (LOW) beat Wall St. forecasts and is trading up over 5% in the pre-market. LOW  reported net earnings of…
Why Allergan Earnings Aren’t Telling the Whole Story
Paul Ausick |

Why Allergan Earnings Aren’t Telling the Whole Story

Allergan reported mixed second-quarter 2016 results and announced share buybacks before markets opened Monday morning.
Paul Ausick |

Rite Aid Earnings View: Its Explosive Turnaround Gains More Steam

Rite Aid reported much better than expected third-quarter fiscal 2015 earnings before markets opened Thursday morning.
Paul Ausick |

Rite Aid Lowers Guidance After Profit Tumbles

Rite Aid reported mixed second-quarter fiscal 2016 results before markets opened Thursday morning.
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
247patrick |

3 Generic Drug Stocks to Watch Amid Improving Market Prospects

Generic price erosion in the United States is expected to continue for the rest of the year.

Top Gaining Stocks

Cboe Global Markets
CBOE • Vol: 1,568,143
New Pluto Global
PSKY • Vol: 12,285,993
Seagate Technology
STX • Vol: 7,378,346
Oracle
ORCL • Vol: 26,317,675
Datadog
DDOG • Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ • Vol: 4,367,433
Clorox
CLX • Vol: 13,260,523
Stryker
SYK • Vol: 4,519,455
Mohawk Industries
MHK • Vol: 1,859,865
Amgen
AMGN • Vol: 3,818,618